Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

ClinicalTrials.gov ID: NCT00708435

Public ClinicalTrials.gov record NCT00708435. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.

Study identification

NCT ID
NCT00708435
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
CSL Behring
Industry
Enrollment
216 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2008
Primary completion
Oct 31, 2010
Completion
Oct 31, 2010
Last update posted
Feb 2, 2014

2008 – 2010

United States locations

U.S. sites
41
U.S. states
19
U.S. cities
36
Facility City State ZIP Site status
Study Site Birmingham Alabama 35248-3280
Study Site Los Angeles California 90033
Study Site San Franciso California 94115
Study Site Newark Delaware 19718
Study Site Orlando Florida 32806
Study Site Tampa Florida 33606
Study Site Chicago Illinois 60612
Study Site Oak Park Illinois 60302
Study Site Hazard Kentucky 41701
Study Site Baltimore Maryland 21201
Study Site Baltimore Maryland 21205
Study Site Boston Massachusetts 02114
Study Site Worchester Massachusetts 01655
Study Site Ann Arbor Michigan 48106
Study Site Royal Oak Michigan 48073
Study Site Duluth Minnesota 55805
Study Site Minneapolis Minnesota 55114
Study Site Jackson Mississippi 39216
Study Site St Louis Missouri 63110
Study Site Albuquerque New Mexico 87131
Study Site Albany New York 12208
Study Site Johnson City New York 13790
Study Site New York New York 10003
Study Site New York New York 10029
Study Site New York New York 10032
Study Site Rochester New York 14642
Study Site Staten Island New York 10305
Study Site Durham North Carolina 27710
Study Site Allentown Pennsylvania 18103
Study Site Hershey Pennsylvania 17033
Study Site Philadelphia Pennsylvania 19107
Study Site Philadelphia Pennsylvania 19140
Study Site West Reading Pennsylvania 19611
Study Site Austin Texas 78701
Study Site El Paso Texas 79905
Study Site 2 Houston Texas 77030
Study Site Houston Texas 77030
Study Site Temple Texas 76508
Study Site Salt Lake City Utah 84132
Study Site Charlottesville Virginia 22908
Study Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00708435, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2014 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00708435 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →